Metagenomi Therapeutics Inc. (MGX)
NASDAQ: MGXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $21.36M
- EPS (TTM)
- -$2.50
- Dividend yield
- None
- 52-week range
- 0.562 – 1.87
- Day range
- 0.5621 – 0.618
- Volume / Avg
- 274.38K / 163.21K
- Beta
- —
- Shares outstanding
- 37.81M
52-week range
MGX stock today
Shares of Metagenomi Therapeutics (MGX) finished lower on Nov 20 at $0.565, a drop of 7.95% or $0.0488 per share, versus the S&P 500's 3.70% decline. At this level, MGX sits near the bottom of its 52-week range of $0.562 to $1.87: 69.8% below the high, set on Dec 22, 2025 and 0.5% above the low. MGX is down 65.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.6%.
Metagenomi Therapeutics has posted a net loss over the last twelve months (EPS of -$2.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Metagenomi Therapeutics
Company profileMetagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jian Irish M.B.A., Ph.D.
- Headquarters
- EmeryVille, CA
- Employees
- 113
- IPO year
- 2024
- Website
- metagenomi.co
Financial highlights
Full financialsIn fiscal 2025, Metagenomi Therapeutics generated $25.2 million in revenue, down 51.8% from fiscal 2024, the first decline in the 3 years shown. Metagenomi Therapeutics reported a net loss of $87.9 million, compared with a loss of $78.1 million a year earlier. Operating margin was -380.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $25.21M | $52.30M | $44.76M |
| Growth | -51.79% | +16.84% | — |
| Net income | $-87.87M | $-78.06M | $-68.25M |
| EPS (diluted) | $-2.36 | $-2.36 | $-20.05 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$7.00+1138.94%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.56 vs $-0.74
- Surprise
- +24.32%
MGX news
All MGX news- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual MeetingGlobeNewswire
- Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceGlobeNewswire
Metagenomi Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CVMCel-Sci Corporation | 1.21 | -17.69% | $21.28M | vs MGX |
| EVAXEvaxion A/S ADR | 2.25 | +10.84% | $20.75M | vs MGX |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs MGX |
| PTHSPelthos Therapeutics Inc. | 6.38 | -8.73% | $25.08M | vs MGX |
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs MGX |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs MGX |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs MGX |
| ESLAEstrella Immunopharma Inc. | 0.321 | -5.70% | $14.11M | vs MGX |
Indexes, lists and sector
Metagenomi Therapeutics stock FAQ
What is Metagenomi Therapeutics's stock price today?
MGX last traded at $0.565 as of Nov 20, 4:00 PM EST, down 7.95% on the day. Prices are delayed at least 15 minutes.
Who is Metagenomi Therapeutics's CEO?
Dr. Jian Irish M.B.A., Ph.D. is the chief executive officer of Metagenomi Therapeutics Inc., which has about 113 employees.
What is the MGX 52-week high?
The 52-week high for MGX is $1.87 and the 52-week low is $0.562. The stock is currently 69.8% below its high.